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ABSTRACT  65 
Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is 66 
mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of 67 
rapamycin (mTOR) inhibitors and/or chemotherapy.  68 
Objective: To obtain an overview of clinical strategies about the current treatment of KS. 69 
Methods: We conducted a multicenter retrospective cohort study including 145 solid organ 70 
transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding 71 
first-line treatment and response at 6 months. 72 
Results: Ninety five percent, 28% and 16% of patients had reduction of immunosuppression, 73 
conversion to mTOR inhibitor and chemotherapy, respectively. Patients treated with 74 
chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. Overall, 75 
83% of patients had response at 6 months including 40% complete responses (CR). 76 
Limitations: The retrospective design of the study. 77 
Conclusion: Currently available therapeutic options seem to be effective to control KS in a 78 
majority of patients. Tapering down the immunosuppressive regimen remains the cornerstone 79 
of KS management. 80 
  81 
4
 
 
 
INTRODUCTION 82 
As graft maintenance requires continuous immunosuppressive therapy, solid organ transplant 83 
recipients (OTRs) are at high risk of developing various types of cancer, particularly those 84 
associated with viral infections1. Kaposi sarcoma(KS) is a lymphatic endothelium-derived 85 
tumor associated with human herpes virus type 8(HHV-8) promoted by immunosuppression. 86 
Most cases of post-transplant KS arise as a result of HHV-8 reactivation triggered by drug-87 
induced immunosuppression2,3, resulting in a 200-fold higher risk in OTRs than in the general 88 
population4. In the 1990s, mortality of KS was high, estimated to be 57% in patients with 89 
visceral extension of the disease5,6. Since then, post-transplant KS management has largely 90 
changed, with greater emphasis on minimization of immunosuppression rather than use of 91 
chemotherapy, but current mortality rates from post-transplant KS are unknown. Therapeutic 92 
management is still a challenge, as it requires both controlling the disease whilst maintaining 93 
graft function.  94 
Reduction of immunosuppression(IS) is an effective therapeutic option to reduce occurrence 95 
of malignancies in OTRs7, but is limited by the risk of graft rejection. In KS, remission after 96 
decrease of IS alone ranged from 30% to 50% in retrospective series6,8. Moreover, all 97 
immunosuppressive drugs do not carry the same risk of malignancies; particularly, 98 
mammalian target of rapamycin inhibitors(mTORi) have both immunosuppressive effects and 99 
direct antineoplastic effects9. Sirolimus has been associated with reduced occurrence of skin 100 
cancers, including KS, and to a lesser extent non skin malignancies10-12. 101 
Therapy for post-transplant KS has changed over the past two decades. In 2005, conversion to 102 
mTORi was shown to have a therapeutic effect: conversion from calcineurin inhibitors (CNI) 103 
and/or purine antagonists to sirolimus induced responses in 72-100% of patients13,14. 104 
However, relapse and the apparent absence of remission in patients with visceral KS were 105 
reported in a significant proportion of patients treated with sirolimus 14,15. Chemotherapy is 106 
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usually required in patients with visceral involvement or rapidly evolving KS and their use 107 
has been best evaluated in AIDS-related KS16,17. The therapeutic armamentarium against post-108 
transplant KS is now based upon 3 axes –reduction of IS, conversion to mTORi and use of 109 
chemotherapy. However, neither comparative prospective trials nor retrospective studies have 110 
been conducted in post-transplant KS, and no consensus guidelines are available.  111 
We conducted a retrospective study amongst expert European centers belonging to the Skin 112 
Care in Organ Transplant Patients, Europe (SCOPE)network, in order to obtain an overview 113 
of the efficacy of treatment and prognosis in post-transplant KS. 114 
 115 
  116 
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MATERIALS AND METHODS 117 
Patients 118 
This multicenter retrospective study was conducted in 15 transplant centers in 6 countries 119 
(France, United Kingdom, Turkey, Belgium, Netherlands and Spain). The study was approved 120 
by Ethics Committees in each country. 121 
Solid OTRs with a pathologically-confirmed diagnosis of post-transplant KS diagnosed 122 
between 1985 and 2011 were included. Patients with HIV were not included. 123 
Clinical data were collected through a questionnaire completed from medical records, 124 
included demographic data, transplantation data, characteristics of KS, KS therapeutic 125 
management and response to treatment. KS extension was defined as visceral (at least one site 126 
among: lymph node, pulmonary or other visceral organ involvement) or not (for patients with 127 
cutaneous and/or mucosal only). First-line therapeutic management was defined as systemic 128 
care given in the first two months after KS diagnosis. Therapeutic options were: reduction of 129 
IS, conversion to mTORi and/or chemotherapy. Reduction of IS included dose reduction or 130 
drug withdrawal for corticosteroids, mycophenolate mofetil (MMF), azathioprine or CNI 131 
(cyclosporine, tacrolimus).  132 
Response to KS first-line management at 6 months was classified as complete response (CR), 133 
partial response (PR), stable disease (SD) or progressive disease (PD) following the Physician 134 
Global Assessment 18. 135 
 136 
Statistical analyses  137 
Characteristics of treatment groups were compared using Fisher’s exact tests, Wilcoxon rank-138 
sum tests or Kruskall-Wallis tests. Progression-free survival (PFS) was defined as the time 139 
delay between the first therapeutic decision to first evidence of disease progression or death, 140 
whichever occurred first. Patients were otherwise censored at their last follow-up date. 141 
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Overall survival(OS) was defined as the time between KS diagnosis and death. PFS and OS 142 
were assessed using Kaplan Meier estimator. Graft loss was defined as the occurrence of a 143 
second organ transplantation or hemodialysis; the cumulative incidence of graft loss was 144 
analyzed in a competing risks framework, with death as competing event. 145 
To account for confounding due to baseline imbalance in prognostic factors in the comparison 146 
of PFS between patients receiving mTORi to those not receiving mTORi, two approaches 147 
were used. First, inverse probability of treatment weighting(IPTW) was used to reconstruct 148 
pseudo-populations with similar baseline characteristics. Adjusted Kaplan-Meier curves were 149 
then estimated19, and a Cox model with robust variance estimator was used for comparison. 150 
Second, regression adjustment using Cox models was used. Variables used were predefined 151 
potential prognostic variables (mucosal KS, lymph node involvement, symptomatic visceral 152 
KS, CMV infection, CMV prophylaxis, HSV prophylaxis). HHV8 viral load was not used due 153 
to too many missing data. Missing covariates were handled through multiple imputation by 154 
chained equations20,21. Fifty imputed datasets were created, and analyzed separately. Results 155 
were then pooled over the imputations according to Rubin’s rule.  156 
Statistical analyses were performed using the R statistical software version 3.2(The R 157 
Foundation for Statistical Computing, Vienna, Austria). 158 
  159 
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RESULTS 160 
Patient characteristics 161 
145 patients with post-transplant KS diagnosed between February 1985 and April 2011 were 162 
enrolled (France, n=109; United-Kingdom, n=14; Turkey, n=9; Belgium, n=7; Netherlands, 163 
n=4; Spain, n=2). Ninety-one patients were diagnosed with KS after 2005, when the first 164 
study highlighting the benefits of mTORi in post-transplant KS was reported13. Baseline 165 
characteristics are summarized in Table 1. Seventy-six percent of patients were male, with a 166 
median age of 53 years. Most patients were kidney transplant recipients (89%).  167 
KS developed within a median time of 17 months after transplantation (IQR,9-38). 168 
Prior history of primary HHV-8 infection was reported in two patients only. All patients were 169 
receiving immunosuppressive therapies, including a CNI for 92%. Four patients had already 170 
been receiving mTOR inhibitor therapy before KS diagnosis.  171 
Fifty-one percent of patients had visceral KS, which was symptomatic for 20 patients 172 
(14%). Pulmonary KS was reported in 20% of patients. 173 
 174 
First-line therapeutic management 175 
First-line therapeutic management was highly variable between patients (Figure 1). 176 
Nevertheless, most patients shared the common feature of having reduction of IS (95%), 177 
which included dose reduction or drug withdrawal for CNI, MMF, azathioprine or 178 
corticosteroids. Conversion to mTORi was performed in 28% of patients, mostly in 179 
association with reduction of other drugs. Among patients whose KS was diagnosed after 180 
2005 (n=91), 67% had conversion to mTORi, vs. 3% among patients before 2005. 181 
Chemotherapy, usually required for severe KS22,23, was used as first line for 23 182 
patients (16%), in addition to reduction of IS (n=12, 8%) or conversion to mTORi (n=10, 183 
7%). Cytotoxic agents included liposomal doxorubicin (n=9), bleomycin monotherapy (n=4), 184 
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ABV (adriamycin, bleomycin, vinblastine, n=5), vinblastine (n=2), paclitaxel (n=1), 185 
bleomycin and vinblastine (n=1) and vindesine (n=1).  186 
In addition, local treatments were reported in 15 patients (surgery, n=8; radiotherapy, 187 
n=5; imiquimod, n=2).  188 
 189 
Characteristics associated with first-line therapeutic management of KS 190 
Given that 95% of patients had reduction of IS, we defined 4 groups of patients among the 191 
therapeutic options, i.e. conversion to mTORi and use chemotherapy. Specifically, Group 1 192 
(n=92), no mTORi conversion, no chemotherapy; Group 2 (n=13), no mTORi conversion, 193 
with chemotherapy; Group 3 (n=30), mTORi conversion, no chemotherapy; Group 4 (n=10), 194 
mTORi conversion, with chemotherapy. Group 1 included almost exclusively patients with 195 
reduction of IS (97%), which included dose reduction or withdrawal for CNI (n=54), AZA 196 
(n=39), MMF (n=11) and/or corticosteroids (n=16). Characteristics of patients in these four 197 
subgroups are summarized in Table 2.  198 
Some characteristics related to KS extent were significantly different between groups. 199 
The proportion of patients having symptomatic visceral KS or lymph node involvement was 200 
significantly higher in Group 4 than in Groups 1, 2, 3 (P<0.0001). Fifty-five percent of 201 
patients with symptomatic visceral KS vs.10% of patients without symptomatic visceral KS, 202 
were treated with chemotherapy as first line treatment. Thus, Group 4 was mostly composed 203 
of patients with visceral KS: 67% and 90% of patients had symptomatic visceral KS and 204 
lymph node involvement, respectively, vs. 6% and 20% of patients in Group 1. Irrespective of 205 
chemotherapy use, patients who received mTORi also had more advanced disease, with a 206 
higher proportion of symptomatic visceral lesions (P=0.027), more lymph node involvement 207 
(P=0.051) and more visceral lesions (P=0.035).  208 
 209 
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KS response to first-line therapeutic management 210 
Among 137 evaluable patients, 83% had response to the treatment at 6 months, including 40% 211 
with CR and 43% with PR (Figure 2). CR occurred more frequently in patients without 212 
visceral involvement (47%) than in patients with visceral disease (30%), while PR was more 213 
frequent in patients with visceral involvement (51% vs. 31%). 11% of patients experienced 214 
PD at 6 months. For patients who had visceral disease (n=73), 55 were treated with only 215 
reduced IS or mTORi and 18 received chemotherapy. 71 patients were evaluable for response. 216 
Of the 18 patients treated with chemotherapy, 5 (28%) had a complete response, 8 (44%) had 217 
a partial response. Among the 53 evaluable patients with visceral disease not treated with 218 
chemotherapy, 17 (32%) had PR and 29 (55%) had CR. 219 
The two most used therapeutic options, which were reduction of IS (97% of patients in 220 
Group 1), and reduction of IS associated with conversion to mTORi (90% of patients in 221 
Group 3), had a similar response rate of 86%. Conversion to mTORi induced 17% CR and 222 
69% PR. However, patients who did not receive mTORi achieved more CR (P=0.0002) but 223 
not more overall responses (CR+PR) (Figure 2).  224 
Bearing in mind that patients’ characteristics were different between treatment groups 225 
(Table 2), response rates were similar with chemotherapy. In patients treated with conversion 226 
to mTORi, 17% and 69% had CR and PR respectively, while those who had additional 227 
chemotherapy had 10% of CR and 70% of PR. Among patients without conversion to 228 
mTORi, response rates were lower for those treated with chemotherapy (62% vs. 86%). 229 
Patients with KS relapse or who progressed upon first line treatment (n=52) were 230 
treated with chemotherapy (n=25, 52%), additional reduction of immunosuppression (n=24, 231 
46%) and/or switch to mTORi (15%).  232 
 233 
Survival 234 
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The median follow-up time was 91 months from KS diagnosis (7.6 years, range 1 to 276 235 
months). During follow-up, 37 patients died, including 4 deaths due to KS (3%) and 3 of 236 
unknown causes. OS was 82% at 5 years(95%CI:75-89%), and 64% at 10 years(95%CI:54-237 
75%). OS was not related to KS extent at diagnosis.  238 
Differences in PFS were found between the four Groups (P=0.0008) (Figure 3B), with better 239 
PFS in Group 1 patients. However, treatment groups differed according to patient baseline 240 
characteristics, specifically the extent of disease (Table 2). To account for this confounding 241 
due to baseline imbalance in potential prognostic factors, IPTW estimators and regression 242 
adjustment were used to compare PFS between patients receiving mTORi or not (but not 243 
chemotherapy as this group was too small sample size). Results were similar for unadjusted, 244 
IPTW and adjusted analyses, with hazard ratios(HRs) for mTORi vs. no mTORi of 245 
2.18(95%CI:1.18-4.05), 2.22(1.23-4.03) and 2.45(1.29-4.645), respectively (Figure 3).  246 
 247 
Graft survival 248 
Similar analyses were performed to study the risk of graft failure related to KS management. 249 
Graft loss occurred in 34 patients. Across the 4 groups, the cumulative incidence of graft loss 250 
was not different (P=0.99, Gray test). Using IPTW, the HR of graft rejection for mTORi vs. 251 
no mTORi was not significantly increased nor decreased (HR 0.69; 95% CI: 0.20-2.34).  252 
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DISCUSSION 253 
In this study, patient data from 15 centers across Europe were pooled to obtain an overview of 254 
post-transplant KS management and responses to treatment. Treatment was mostly based on 255 
IS reduction and conversion to mTORi, inducing response in more than 80% of patients. KS-256 
related deaths rarely occurred, suggesting that KS can be effectively controlled.  257 
mTORi were included in the armamentarium of immunosuppressive drugs since 258 
200024. In 2005, Stallone and colleagues demonstrated that mTOR inhibitors induced CR in 259 
100% of 15 patients with post-transplant KS13. This effective strategy based on CNI 260 
withdrawal and switch to mTORi was confirmed in other studies14,25-27, although Lebbé et al. 261 
reported a significant proportion of relapses (3/14 patients) and resistance in patients with 262 
visceral KS14. Switch to mTORi became part of the standard management strategy of post-263 
transplant KS22,23. In the present study, conversion to mTORi induced responses in more than 264 
80% of patients. However these patients -who certainly had more visceral KS-experienced 265 
fewer CRs than those who did not receive mTORi. Statistical maneuvers to adjust for 266 
important prognostic factors such as disease extent were undertaken. Despite this, the long-267 
term risk of disease progression remained significantly higher in OTR who received mTORi.  268 
Reduction of IS is still the cornerstone of post-transplant KS management. In this 269 
study almost all patients had minimization of IS, and 50% of CR had been achieved solely by 270 
a decrease of IS. Clinical benefits reported in mTORi conversion and/or chemotherapy groups 271 
might be partially attributable to decrease of IS. Moreover, in contrast to prospective studies, 272 
reduction of immunosuppressive therapies is highly heterogeneous in retrospective studies. 273 
Beyond the level of IS, the type of regimen also contributes to the risk of post-transplant 274 
malignancies. CNI were found to have direct oncogenic properties 28-30 and CNI withdrawal 275 
was associated with risk reduction of post-transplant malignancies 10. Conversely, in KS there 276 
is a growing amount of evidence suggesting that mTORi have direct anti-tumor cell effects 277 
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that are independent of the immune system 31,32. In contrast, everolimus was unsuccessfully 278 
tested in classic KS suggesting that immunosuppressive effects of mTORi could override its 279 
antineoplastic properties in immunocompetent patients, while this appears not to be the case 280 
in immunocompromised patients 33,34. 281 
Chemotherapy is usually required in cases of extensive or symptomatic visceral KS 22. 282 
In our cohort, chemotherapy was used for advanced KS (visceral involvement and/or rapid 283 
progression) in fewer than 20% of patients. Response rates were increased in association with 284 
mTORi conversion, suggesting that in patients with visceral KS, combination of mTORi and 285 
short-term chemotherapy could be an effective strategy. 286 
This study represents the largest case series to focus on post-transplant KS and the 287 
first to report first-line practices. The retrospective design limits detailed comparison of data 288 
as it could not be ruled out that different outcomes in treatment groups were due to 289 
unmeasured confounding factors. Screening for KS extension at diagnosis was performed 290 
upon local practices, and might be heterogeneous between centers. Missing information as KS 291 
treatment received after the first 2 months limited quantity and quality of interpretable data. 292 
For instance, data regarding the optimal time to conversion to mTORi after KS diagnosis or 293 
the total amount of corticosteroids received after KS diagnosis, which is associated with KS 294 
occurrence and outcome 35,  could not be studied in detail. Finally, the study population was 295 
probably heterogeneous because of the extended inclusion period, during which practices 296 
regarding immunosuppressive regimens and KS therapeutic strategy have evolved, 297 
particularly pre- and post-200513. 298 
 This study provides insight into clinical practices in post-transplant KS management, 299 
which is based on reduction of IS in addition to conversion to mTORi, and/or chemotherapy. 300 
The signal from our data that mTORi conversion may be associated with a higher risk of 301 
progression is complicated by multiple potential confounders including KS extent, but is an 302 
14
 
 
 
indication that further prospective studies are now warranted to precisely assess the long-term 303 
benefits of conversion to mTORi in the management of post-transplant KS. 304 
  305 
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Table 1: Patients and Kaposi sarcoma characteristics 409 
 Characteristics Overall population 
N=145 
P
A
T
IE
N
T
S
 C
H
A
R
A
C
T
E
R
IS
T
IC
S
 
Age, years (IQR) 53 (44 to 62) 
Male gender, n (%) 110 (76) 
Region of birth, n (%) 
Sub-Saharan Africa/Caribbean 
Mediterranean 
Northern Europe 
NA 
 
76 (56) 
47 (35) 
13 (9) 
9 
Transplanted organ, n (%)  
Kidney  
Heart  
Liver 
Lung 
Other 
NA 
 
127 (89) 
3 (2) 
5 (3) 
3 (2) 
5 (4) 
2 
 Induction therapy, n (%) 
Yes  
No 
NA 
Treatment of induction 
Steroids 
ATG 
Anti-IL-2 receptor  
OKT3 
 
102 (81)  
24 (19) 
19 
 
76 (60) 
51 (40) 
33 (26) 
8 (6) 
Rejection episodes, n (%) 
No 
Yes 
NA 
Treatment of rejection 
Steroids 
ATG 
OKT3 
Rituximab 
IVIG 
 
79 (59) 
56 (41) 
10 
 
47 (70) 
10 (15) 
3 (5) 
1 (2) 
3 (11) 
K
S
 C
H
A
R
A
C
T
E
R
IS
T
IC
S
 
Immunosuppressive drugs at KS diagnosis 
CS + CNI + PI 
CS + CNI 
CS + PI 
CS + mTOR inh + CNI or PI 
Other 
 
109 (76) 
20 (14) 
8 (6) 
4 (3) 
4 (3) 
KS extension, n (%) 
Cutaneous only 
Mucosal (+/- cutaneous, w/o visceral) 
Visceral (+/- cutaneous/mucosal) 
NA 
Lymph node involvement, n (%) 
Gastrointestinal involvement 
 
60 (42) 
11 (8) 
73 (50) 
1 
39 (33) 
47 (36%) 
19
 
 
 
 
Pulmonary KS, n (%) 
29 (20) 
HHV8 detection 
Positive HHV8 viral load, n (%) 
Positive LANA IHC, n (%) 
Positive latent IF serology, n (%) 
 
29 (54) 
88 (98) 
74 (91) 
 410 
ATG, antithymocyte globulin; CNI, calcineurin inhibitor; CS: corticosteroids; IF, 411 
immunofluorescence; IHC, immunohistochemistry; IL-2, interleukine-2; IVIG, intravenous 412 
immunoglobulin; KS, Kaposi sarcoma; mTOR inh: mammalian target of rapamycin inhibitor; 413 
NA, not available; OKT3, anti-CD3 antibody; PI, purine inhibitor. 414 
Other immunosuppressive drugs at KS diagnosis: no treatment (n=1), CNI alone (n=1), 415 
CNI+PI (n=1), unknown treatment (n=1). 416 
 417 
  418 
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Table 2: Characteristics of patients in the 4 first-line treatment groups 419 
 420 
Variable (n, %) 
 
First line treatment of KS 
P 
No conversion to mTOR 
inhibitor 
Conversion to mTOR 
inhibitor 
 
Group 1: No 
chemotherapy 
Group 2: With 
chemotherapy 
Group 3: No 
chemotherapy 
Group 4:With 
chemotherapy 
 
Mean age (SD), years 52.8 (13.3) 42.2 (17.7) 55.9 (13.7) 47.5 (10.4) 0.010 
Male gender 70 (76) 12 (92) 22 (73) 6 (60) 0.34 
Sub-Saharan/Caribbean 
origin 
43 (49) 4 (31) 15 (58) 9 (90) 0.030 
Median time to KS 
diagnosis (IQR), months 
19 (10 to 40) 14 (8 to 39) 15 (8 to 35) 16 (10 to 24) 0.76 
Mucosal KS 14 (15) 2 (15) 6 (20) 2 (20) 0.87 
Lymph node involvement 18 (20) 5 (38) 7 (23) 9 (90) <0.000 1 
Symptomatic visceral KS 5 (6) 5 (38) 4 (14) 6 (67) <0.000 1 
HSV prophylaxis 23 (33) 5 (56) 17 (61) 7 (70) 0.021 
Overall 92 (63) 13 (9) 30 (21) 10 (7) - 
 421 
 422 
IQR, interquartile range; KS, Kaposi sarcoma; mTOR, mammalian target of rapamycin 423 
 424 
 425 
 426 
  427 
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Figure legends 428 
Figure 1: First-line treatment combination for post-transplant Kaposi sarcoma. 429 
Strategies included combination of reduction of immunosuppression, conversion mTOR 430 
inhibitors and chemotherapy. 431 
 432 
Figure 2: Response at 6 months to first-line treatment. 433 
Responses classified as complete response (CR), partial response (PR), stable disease (SD) 434 
and progressive disease (PD) in the response-evaluable population (n=137) are plotted for 435 
each group of treatment. 436 
 437 
Figure 3: Survival analyses for patients with post-transplant Kaposi sarcoma.  438 
Left, Unadjusted Kaplan-Meier curves for progression-free survival according to first-line 439 
treatment; right, Adjusted Kaplan-Meier curves for progression-free survival between patients 440 
receiving mTOR inhibitors or not. The group of patients receiving chemotherapy was too 441 
small to be included in the adjusted analyses. 442 
 443 
 444 
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